Assessments and endpoints
DISEASE, PLASMA CELL INFILTRATION
The blinded IRC continued to review, after the interim analysis, disease assessments for response and progression performed by central laboratory for M-protein quantification, central review of radiological assessments done locally, and local bone marrow aspiration for plasma cell infiltration when applicable. The Hydrashift 2/4 Isa immunofixation electrophoresis (IFE) assay (Sebia, Lisses Evry Cedex, France) [MRD was evaluated by next-generation sequencing clonoSEQ Assay (Adaptive Biotechnologies, Seattle, WA, USA) with a minimum sensitivity of 10